22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ANIKA THERAPEUTICS INC. › 2024-2025

ANIKA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ANIKA THERAPEUTICS INC.’s Form 8-K, filed June 24, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 11Ballot items
  • 187Asset managers, any item
  • 2,024Fund votes
  • June 20, 2025Main meeting date

Results at a glance

Meeting of June 20, 2025: 6 items on ANIKA THERAPEUTICS INC.’s Form 8-K, filed June 24, 2025: 2 approved · 4 passed (calculated).

Meeting of July 9, 2024: 5 items on ANIKA THERAPEUTICS INC.’s Form 8-K, filed July 11, 2024: 1 approved · 4 passed (calculated).

Dissent

Significant dissent: 1 director (20.2% against).

Notable dissent: 1 director (19.6% against); 1 say-on-pay vote (76.8% support); 1 other board item (23.9% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2024-2025 2025-2026

Activist investors: Caligan Partners (13D, 9.9%, as of January 27, 2026)

Explore ANIKA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ANIKA THERAPEUTICS INC.

These tallies are ANIKA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. ANIKA THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

ANIKA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 20, 2025 (Form 8-K, filed June 24, 2025)
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Cheryl R. Blanchard, Ph.D. 8,754,7172,139,21551,074 --1,406,800 80%Passed (calculated)—
Elect Director: Joseph H. Capper 10,521,730387,38535,891 --1,406,800 96%Passed (calculated)—
Elect Director: Glenn R. Larsen, Ph.D. 8,712,9402,202,44129,625 --1,406,800 80%Passed (calculated)—
2. The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 12,076,726248,61026,470 --0 98%Approved—
3. Stockholders voted, on a non-binding, advisory basis, to approve the compensation paid to the Company's named executive officers as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and 8,374,0762,529,08141,849 --1,406,800 77%Passed (calculated)—
4. The Amendment with respect to the 2017 Plan 8,297,5632,608,92538,518 --1,406,800 76%Approved—

Source: ANIKA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 24, 2025 — read the filing on EDGAR.

ANIKA THERAPEUTICS INC. — official shareholder meeting results, meeting held July 9, 2024 (Form 8-K, filed July 11, 2024)
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sheryl L. Conley 10,713,825415,05527,858 --1,230,326 96%Passed (calculated)—
Elect Director: William R. Jellison 11,092,81813,08550,835 --1,230,326 99.9%Passed (calculated)—
Elect Director: Stephen O. Richard 10,205,467924,21327,058 --1,230,326 92%Passed (calculated)—
2. The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 12,337,37643,6546,034 --0 99.6%Approved—
3. Stockholders voted, on a non-binding, advisory basis, to approve the compensation paid to the Company's named executive officers as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and 11,020,273129,7176,748 --1,230,326 99%Passed (calculated)—

Source: ANIKA THERAPEUTICS INC., Form 8-K, filed with the SEC on July 11, 2024 — read the filing on EDGAR.

How asset managers voted at the ANIKA THERAPEUTICS INC. 2024-2025 meetings

187 asset managers disclosed a vote on at least one ANIKA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Cheryl R. Blanchard, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 20, 2025.

Combines 3 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%AGAINST
FOR: 8,754,717AGAINST: 2,139,215
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of three Class II Directors: Cheryl R. Blanchard, Ph.D.

ANIKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Cheryl R. Blanchard, Ph.D.”): 8,754,717 for, 2,139,215 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 2,271,764 for, 1,202 against, 828 not voted.

FOR
FOR: 2,271,764AGAINST: 1,202NOT VOTED: 828
Largest asset managers voting on “Election of three Class II Directors: Cheryl R. Blanchard, Ph.D.” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard765,1290 00For
BlackRock584,2290 00For
Fidelity311,9930 00For
Charles Schwab136,6170 00For
MFS45,4490 00For
Equitable43,5280 00For
TIAA40,9460 00For
American Century38,6490 00For
SEI29,3870 00For
Columbia Threadneedle24,9370 00For
QUANTITATIVE MASTER SERIES LLC22,6500 00For
Nationwide21,8020 00For
Goldman Sachs20,6640 00For
Bridge Builder Trust19,2710 00For
Thrivent15,8890 00For
FORUM FUNDS II14,9110 00For
Lincoln Financial12,3810 00For
State Street10,5080 00For
Northern Trust10,3370 00For
GuideStone9,9040 00For
MASTER INVESTMENT PORTFOLIO8,9590 00For
Global X7,8910 00For
WisdomTree7,6120 00For
John Hancock7,1930 00For
AIG/SunAmerica6,6220 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Glenn R. Larsen, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 20, 2025.

Combines 3 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%AGAINST
FOR: 8,712,940AGAINST: 2,202,441
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of three Class II Directors: Glenn R. Larsen, Ph.D.

ANIKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Glenn R. Larsen, Ph.D.”): 8,712,940 for, 2,202,441 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 2,251,598 for, 21,368 against, 828 not voted.

FOR
FOR: 2,251,598AGAINST: 21,368NOT VOTED: 828
Largest asset managers voting on “Election of three Class II Directors: Glenn R. Larsen, Ph.D.” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard765,1290 00For
BlackRock584,2290 00For
Fidelity311,9930 00For
Charles Schwab136,6170 00For
MFS45,4490 00For
Equitable24,27819,250 00Mixed
TIAA40,9460 00For
American Century38,6490 00For
SEI29,3870 00For
Columbia Threadneedle24,9370 00For
QUANTITATIVE MASTER SERIES LLC22,6500 00For
Nationwide21,8020 00For
Goldman Sachs20,6640 00For
Bridge Builder Trust19,2710 00For
Thrivent15,8890 00For
FORUM FUNDS II14,9110 00For
Lincoln Financial12,3810 00For
State Street10,5080 00For
Northern Trust10,3370 00For
GuideStone9,9040 00For
MASTER INVESTMENT PORTFOLIO8,9590 00For
Global X7,8910 00For
WisdomTree7,6120 00For
John Hancock7,1930 00For
AIG/SunAmerica6,6220 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Joseph H. Capper

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 20, 2025.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 10,521,730AGAINST: 387,385
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of three Class II Directors: Joseph H. Capper

ANIKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Joseph H. Capper”): 10,521,730 for, 387,385 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 2,252,454 for, 20,512 against, 828 not voted.

FOR
FOR: 2,252,454AGAINST: 20,512NOT VOTED: 828
Largest asset managers voting on “Election of three Class II Directors: Joseph H. Capper” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard765,1290 00For
BlackRock584,2290 00For
Fidelity311,9930 00For
Charles Schwab136,6170 00For
MFS45,4490 00For
Equitable24,27819,250 00Mixed
TIAA40,9460 00For
American Century38,6490 00For
SEI29,3870 00For
Columbia Threadneedle24,9370 00For
QUANTITATIVE MASTER SERIES LLC22,6500 00For
Nationwide21,8020 00For
Goldman Sachs20,6640 00For
Bridge Builder Trust19,2710 00For
Thrivent15,8890 00For
FORUM FUNDS II14,9110 00For
Lincoln Financial12,3810 00For
State Street10,5080 00For
Northern Trust10,3370 00For
GuideStone9,9040 00For
MASTER INVESTMENT PORTFOLIO8,9590 00For
Global X7,8910 00For
WisdomTree7,6120 00For
John Hancock7,1930 00For
AIG/SunAmerica6,6220 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Stephen O. Richard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held July 9, 2024.

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 10,205,467AGAINST: 924,213
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: Election of three Class I Directors: Stephen O. Richard

ANIKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen O. Richard”): 10,205,467 for, 924,213 against, per its Form 8-K filed July 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 2,841,556 for, 379,792 against.

FOR
FOR: 2,841,556AGAINST: 379,792
Largest asset managers voting on “Election of three Class I Directors: Stephen O. Richard” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard763,9990 00For
Dimensional642,2010 00For
BlackRock548,7530 00For
Fidelity330,7780 00For
TIAA176,5470 00For
Charles Schwab0147,890 00Against
FRANKLIN VALUE INVESTORS TRUST0129,315 00Against
SEI074,943 00Against
MFS47,5510 00For
Virtus45,5790 00For
Equitable25,34318,800 00Mixed
QUANTITATIVE MASTER SERIES LLC27,2840 00For
Thrivent26,2060 00For
American Century22,7300 00For
Lincoln Financial22,7210 00For
Bridge Builder Trust19,8160 00For
FORUM FUNDS II17,3140 00For
Goldman Sachs11,8770 00For
Northern Trust11,4060 00For
Voya9,3530 00For
State Street8,6341 00For
MASTER INVESTMENT PORTFOLIO7,5080 00For
AIG/SunAmerica7,4510 00For
AQR7,1580 00For
John Hancock6,9980 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: William R. Jellison

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held July 9, 2024.

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 11,092,818AGAINST: 13,085
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: Election of three Class I Directors: William R. Jellison

ANIKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: William R. Jellison”): 11,092,818 for, 13,085 against, per its Form 8-K filed July 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 3,221,348 for.

FOR
FOR: 3,221,348
Largest asset managers voting on “Election of three Class I Directors: William R. Jellison” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard763,9990 00For
Dimensional642,2010 00For
BlackRock548,7530 00For
Fidelity330,7780 00For
TIAA176,5470 00For
Charles Schwab147,8900 00For
FRANKLIN VALUE INVESTORS TRUST129,3150 00For
SEI74,9430 00For
MFS47,5510 00For
Virtus45,5790 00For
Equitable44,1430 00For
QUANTITATIVE MASTER SERIES LLC27,2840 00For
Thrivent26,2060 00For
American Century22,7300 00For
Lincoln Financial22,7210 00For
Bridge Builder Trust19,8160 00For
FORUM FUNDS II17,3140 00For
Goldman Sachs11,8770 00For
Northern Trust11,4060 00For
Voya9,3530 00For
State Street8,6350 00For
MASTER INVESTMENT PORTFOLIO7,5080 00For
AIG/SunAmerica7,4510 00For
AQR7,1580 00For
John Hancock6,9980 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: Sheryl L. Conley

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held July 9, 2024.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 10,713,825AGAINST: 415,055
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Election of three Class I Directors: Sheryl L. Conley

ANIKA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Sheryl L. Conley”): 10,713,825 for, 415,055 against, per its Form 8-K filed July 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 3,184,031 for, 20,003 against.

FOR
FOR: 3,184,031AGAINST: 20,003
Largest asset managers voting on “Election of three Class I Directors: Sheryl L. Conley” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard763,9990 00For
Dimensional642,2010 00For
BlackRock548,7530 00For
Fidelity330,7780 00For
TIAA176,5470 00For
Charles Schwab147,8900 00For
FRANKLIN VALUE INVESTORS TRUST129,3150 00For
SEI74,9430 00For
MFS47,5510 00For
Virtus45,5790 00For
Equitable25,34318,800 00Mixed
QUANTITATIVE MASTER SERIES LLC27,2840 00For
Thrivent26,2060 00For
American Century22,7300 00For
Lincoln Financial22,7210 00For
Bridge Builder Trust19,8160 00For
Goldman Sachs11,8770 00For
Northern Trust11,4060 00For
Voya9,3530 00For
State Street8,6341 00For
MASTER INVESTMENT PORTFOLIO7,5080 00For
AIG/SunAmerica7,4510 00For
AQR7,1580 00For
John Hancock6,9980 00For
Legg Mason6,6750 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

The Amendment with respect to the 2017 Plan

Official resultCOMPENSATIONReported outcome: Approved

Meeting held June 20, 2025.

76% Approved · of votes cast

FOR 76%AGAINST
FOR: 8,297,563AGAINST: 2,608,925
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: APPROVAL OF THE AMENDMENT TO THE ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN.

ANIKA THERAPEUTICS INC.’s own tally for this item (“4. The Amendment with respect to the 2017 Plan”): 8,297,563 for, 2,608,925 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “PROPOSAL 4 Stockholders approved the Amendment with respect to the 2017 Plan.”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of ANIKA THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (2 managers, 24,815 for).

The 52 asset managers below reported 2,064,577 for, 186,508 against, 828 not voted.

FOR
FOR: 2,064,577AGAINST: 186,508NOT VOTED: 828
Largest asset managers voting on “APPROVAL OF THE AMENDMENT TO THE ANIKA THERAPEUTICS, INC. 2017 OMNIBUS INCENTIVE PLAN.” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard765,1290 00For
BlackRock584,2290 00For
Fidelity293,36118,632 00Mixed
Charles Schwab136,6170 00For
MFS045,449 00Against
Equitable43,5280 00For
TIAA040,946 00Against
American Century038,649 00Against
SEI29,3870 00For
Columbia Threadneedle24,9370 00For
QUANTITATIVE MASTER SERIES LLC22,6500 00For
Nationwide21,8020 00For
Goldman Sachs20,6640 00For
Bridge Builder Trust5,67213,599 00Mixed
Thrivent15,8890 00For
Lincoln Financial2,9869,395 00Mixed
State Street7210,436 00Against
Northern Trust10,3370 00For
MASTER INVESTMENT PORTFOLIO8,9590 00For
Global X7,8910 00For
WisdomTree7,6120 00For
John Hancock7,1930 00For
AIG/SunAmerica6,6220 00For
Pacific Life5,9170 00For
Jackson National5,2440 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Stockholders voted, on a non-binding, advisory basis, to approve the compensation paid to the Company's named executive…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Meeting held July 9, 2024.

Combines 6 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 11,020,273AGAINST: 129,717
Details: description as filed, official tally, votes by 149 asset managers

Description as filed by funds: ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

ANIKA THERAPEUTICS INC.’s own tally for this item (“3. Stockholders voted, on a non-binding, advisory basis, to approve the compensation paid to the Company's named executive officers as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussi”): 11,020,273 for, 129,717 against, per its Form 8-K filed July 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 48 asset managers voting on “ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard763,9990 00For
Dimensional642,2010 00For
BlackRock542,6990 00For
Fidelity330,4860 00For
TIAA164,8650 00For
Charles Schwab142,0790 00For
FRANKLIN VALUE INVESTORS TRUST129,3150 00For
SEI71,8730 00For
MFS47,5510 00For
Virtus45,5790 00For
Equitable32,4480 00For
QUANTITATIVE MASTER SERIES LLC27,2840 00For
Thrivent26,2060 00For
American Century22,7300 00For
Lincoln Financial22,7210 00For
Bridge Builder Trust19,8160 00For
FORUM FUNDS II17,3140 00For
Goldman Sachs11,8770 00For
Northern Trust11,4060 00For
Voya9,3530 00For
State Street8,6350 00For
MASTER INVESTMENT PORTFOLIO7,5080 00For
AIG/SunAmerica7,4510 00For
AQR7,1580 00For
John Hancock6,9980 00For

Fund voting reports, all 48 managers: 3,179,730 for. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 123 asset managers voting on “ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Trigran Investments, Inc.1,954,5870 00For
Caligan Partners LP1,360,4500 00For
BlackRock789,7640 00For
BOOTHBAY FUND MANAGEMENT, LLC501,9500 00For
Renaissance474,4540 00For
GEODE CAPITAL MANAGEMENT, LLC336,5440 00For
State Street300,1940 00For
Nuveen176,9160 00For
DE Shaw154,9550 00For
Charles Schwab147,8900 00For
Meros Investment Management, LP143,2940 00For
Ensign Peak Advisors, Inc142,3810 00For
FRANKLIN MUTUAL ADVISERS LLC129,3150 00For
Northern Trust118,9690 00For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP115,2970 00For
SEGALL BRYANT & HAMILL, LLC107,0050 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC104,3870 00For
GLOBEFLEX CAPITAL L P96,4350 00For
Dimensional77,6450 00For
SEI76,2060 00For
Two Sigma71,9770 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM71,1970 00For
AQR64,3450 00For
MELLON INVESTMENTS Corp60,3090 00For
ENVESTNET ASSET MANAGEMENT INC50,6800 00For

Institutional-manager reports, all 123 managers: 8,184,914 for, 22,557 against, 1,448 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Stockholders voted, on a non-binding, advisory basis, to approve the compensation paid to the Company's named executive…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Meeting held June 20, 2025.

Combines 7 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%AGAINST
FOR: 8,374,076AGAINST: 2,529,081
Details: description as filed, official tally, votes by 145 asset managers

Description as filed by funds: ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

ANIKA THERAPEUTICS INC.’s own tally for this item (“3. Stockholders voted, on a non-binding, advisory basis, to approve the compensation paid to the Company's named executive officers as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussi”): 8,374,076 for, 2,529,081 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 51 asset managers voting on “ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock584,2290 00For
Vanguard315,1090 00For
Fidelity298,8380 00For
Charles Schwab136,6170 00For
MFS45,4490 00For
Equitable43,5280 00For
American Century038,649 00Against
TIAA30,0030 00For
SEI29,3870 00For
Columbia Threadneedle24,9370 00For
QUANTITATIVE MASTER SERIES LLC22,6500 00For
Nationwide21,8020 00For
Goldman Sachs20,6640 00For
Thrivent15,8890 00For
FORUM FUNDS II14,9110 00For
Lincoln Financial9,3952,986 00Mixed
State Street10,5080 00For
Northern Trust10,3370 00For
GuideStone9,9040 00For
MASTER INVESTMENT PORTFOLIO8,9590 00For
Global X7,8910 00For
WisdomTree7,6120 00For
John Hancock5,6081,585 00Mixed
AIG/SunAmerica6,6220 00For
Pacific Life5,9170 00For

Fund voting reports, all 51 managers: 1,722,550 for, 56,951 against, 828 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 112 asset managers voting on “ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Trigran Investments, Inc.1,938,4550 00For
Caligan Partners LP01,434,130 00Against
BlackRock822,6460 00For
BOOTHBAY FUND MANAGEMENT, LLC0529,503 00Against
Opaleye Management Inc.490,8880 00For
Renaissance362,1940 00For
GEODE CAPITAL MANAGEMENT, LLC331,5380 00For
State Street187,7320 00For
DE Shaw148,6150 00For
Charles Schwab136,6170 00For
Meros Investment Management, LP111,0560 00For
Northern Trust101,2080 00For
JACOBS LEVY EQUITY MANAGEMENT, INC94,7030 00For
GLOBEFLEX CAPITAL L P87,6000 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM68,0620 00For
Dimensional064,961 00Against
ENVESTNET ASSET MANAGEMENT INC47,7531,563 00For
MELLON INVESTMENTS Corp48,7330 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/45,4490 00For
Wellington41,4580 00For
Nuveen41,3150 00For
American Century038,649 00Against
Asset Management One Co., Ltd.33,7800 00For
STATE OF WISCONSIN INVESTMENT BOARD31,6410 00For
Citadel30,3080 00For

Institutional-manager reports, all 112 managers: 5,572,764 for, 2,078,053 against. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

Meeting held June 20, 2025.

Combines 2 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 12,076,726AGAINST: 248,610
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: RATIFICATION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

ANIKA THERAPEUTICS INC.’s own tally for this item (“2. The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 12,076,726 for, 248,610 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “PROPOSAL 2 Stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 2,272,905 for, 61 against, 828 not voted.

FOR
FOR: 2,272,905AGAINST: 61NOT VOTED: 828
Largest asset managers voting on “RATIFICATION OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED ACCOUNTING FIRM FOR THE FISCAL Y” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard765,1290 00For
BlackRock584,2290 00For
Fidelity311,9930 00For
Charles Schwab136,6170 00For
MFS45,4490 00For
Equitable43,5280 00For
TIAA40,9460 00For
American Century38,6490 00For
SEI29,3870 00For
Columbia Threadneedle24,9370 00For
QUANTITATIVE MASTER SERIES LLC22,6500 00For
Nationwide21,8020 00For
Goldman Sachs20,6640 00For
Bridge Builder Trust19,2710 00For
Thrivent15,8890 00For
FORUM FUNDS II14,9110 00For
Lincoln Financial12,3810 00For
State Street10,5071 00For
Northern Trust10,3370 00For
GuideStone9,9040 00For
MASTER INVESTMENT PORTFOLIO8,9590 00For
Global X7,8910 00For
WisdomTree7,6120 00For
John Hancock7,1930 00For
AIG/SunAmerica6,6220 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

Meeting held July 9, 2024.

Combines 3 wordings of this item as funds reported it.

99.6% Approved · of votes cast

FOR 99.6%
FOR: 12,337,376AGAINST: 43,654
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: Ratification of appointment of Deloitte & Touche LLP as Anika's independent auditor for 2024; and

ANIKA THERAPEUTICS INC.’s own tally for this item (“2. The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 12,337,376 for, 43,654 against — passed, per its Form 8-K filed July 11, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “PROPOSAL 2 Stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 3,221,296 for, 52 against.

FOR
FOR: 3,221,296AGAINST: 52
Largest asset managers voting on “Ratification of appointment of Deloitte & Touche LLP as Anika's independent auditor for 2024; and” at ANIKA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard763,9990 00For
Dimensional642,2010 00For
BlackRock548,7530 00For
Fidelity330,7780 00For
TIAA176,5470 00For
Charles Schwab147,8900 00For
FRANKLIN VALUE INVESTORS TRUST129,3150 00For
SEI74,9430 00For
MFS47,5510 00For
Virtus45,5790 00For
Equitable44,1430 00For
QUANTITATIVE MASTER SERIES LLC27,2840 00For
Thrivent26,2060 00For
American Century22,7300 00For
Lincoln Financial22,7210 00For
Bridge Builder Trust19,8160 00For
FORUM FUNDS II17,3140 00For
Goldman Sachs11,8770 00For
Northern Trust11,4060 00For
Voya9,3530 00For
State Street8,6350 00For
MASTER INVESTMENT PORTFOLIO7,5080 00For
AIG/SunAmerica7,4510 00For
AQR7,1580 00For
John Hancock6,9980 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Largest ANIKA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 14,839,000 shares outstanding at the time of that meeting.

Fund voting reports: top ANIKA THERAPEUTICS INC. shareholders by shares voted on “Election of three Class II Directors: Cheryl R. Blanchard, Ph.D.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.16%
2BlackRock 3.94%
3Fidelity 2.10%
4Charles Schwab 0.92%
5MFS 0.31%
6Equitable 0.29%
7TIAA 0.28%
8American Century 0.26%
9SEI 0.20%
10Columbia Threadneedle 0.17%
Institutional-manager reports: top ANIKA THERAPEUTICS INC. shareholders by shares voted on “ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.”, 2024-2025
#Asset manager % of shares outstanding
1Trigran Investments, Inc. 13.17%
2Caligan Partners LP 9.17%
3BlackRock 5.32%
4BOOTHBAY FUND MANAGEMENT, LLC 3.38%
5Renaissance 3.20%
6GEODE CAPITAL MANAGEMENT, LLC 2.27%
7State Street 2.02%
8Nuveen 1.19%
9DE Shaw 1.04%
10Charles Schwab 1.00%

Reported ANIKA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ANIKA THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock1,519,261 10.24%Form 13F, quarter ended March 31, 2025
Caligan Partners LP1,435,130 9.67%Schedule 13D, filed January 27, 2026
BlackRock, Inc.963,078 6.49%Schedule 13G, filed April 17, 2025
Vanguard Group777,405 5.24%Form 13F, quarter ended March 31, 2025
Dimensional Fund Advisors613,972 4.14%Form 13F, quarter ended March 31, 2025
Renaissance Technologies528,617 3.56%Form 13F, quarter ended March 31, 2025
State Street326,615 2.20%Form 13F, quarter ended March 31, 2025
Trigran Investments, Inc.168,400 1.13%Schedule 13G, filed January 8, 2026
D.E. Shaw167,760 1.13%Form 13F, quarter ended March 31, 2025
Charles Schwab149,935 1.01%Form 13F, quarter ended March 31, 2025

Percentages above are of 14,839,000 shares outstanding, as reported by ANIKA THERAPEUTICS INC. on its Form 10-Q dated June 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ANIKA THERAPEUTICS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held July 9, 2024 and June 20, 2025), 187 asset managers reported votes on at least one of its 11 ballot items in their SEC Form N-PX filings, covering 2,024 separate fund positions. On the most widely held item of the season, voted at the meeting held July 9, 2024 — ADVISORY VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS. — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ANIKA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 11, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ANIKA THERAPEUTICS INC.’s 10-Q dated June 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ANIKA THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ANIKA THERAPEUTICS (ANIK) 2024-2025 Annual Meetings: Vote Results”, https://proxyvotesnow.com/company/anika-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.